Reversine

Reversine is a small synthetic molecule that has been shown to have the ability to dedifferentiate cells, or revert them back to a more primitive state. This molecule was first described in 2004 by a team of researchers at the Scripps Research Institute in California.

History

Reversine was first synthesized and described in 2004 by a team of researchers at the Scripps Research Institute in California. The team was led by Peter G. Schultz, a chemist and biologist known for his work in the field of chemical biology. The discovery of reversine was part of a larger project aimed at developing small molecules that could be used to control cell fate.

Mechanism of Action

Reversine works by inhibiting the activity of certain protein kinases, enzymes that are involved in regulating cell division and differentiation. Specifically, it has been shown to inhibit the activity of Aurora kinases and Polo-like kinase 1, both of which are involved in the process of cell division. By inhibiting these kinases, reversine is able to induce cells to revert back to a more primitive state, a process known as dedifferentiation.

Potential Applications

The ability of reversine to induce dedifferentiation has led to interest in its potential use in regenerative medicine. For example, it could potentially be used to convert differentiated cells, such as skin cells, back into stem cells, which could then be used to regenerate damaged or diseased tissues. However, much more research is needed to fully understand the potential applications and limitations of reversine.

Safety and Side Effects

As with any drug, the safety and potential side effects of reversine are important considerations. While reversine has been shown to be relatively safe in laboratory studies, it has not yet been tested in humans. Therefore, the potential side effects and long-term safety of reversine are not yet known.

See Also

• Dedifferentiation
• Regenerative medicine
• Stem cells
• Aurora kinases
• Polo-like kinase 1

References

Reversine Resources
Latest articles Most recent articles Ongoing trials	Wikipedia